AFP Clinical Answers

VTE, Antiplatelet Therapy, Treatment for Veterans, HIV Prophylaxis, Diabetes Mellitus Screening

 

Am Fam Physician. 2020 Sep 15;102(6):332.

What anticoagulant medications are preferred to treat venous thromboembolism (VTE)?

Direct oral anticoagulants should be used as first-line agents for the treatment of VTE. Low-molecular-weight heparin is recommended as the anticoagulant of choice in patients with cancer and VTE; however, direct oral anticoagulants may be appropriate in select situations.

https://www.aafp.org/afp/2019/1001/p426.html

Is there an indication for dual antiplatelet therapy after stroke or transient ischemic attack?

A 10- to 21-day course of dual antiplatelet therapy reduces stroke recurrence and improves quality of life after mild stroke or high-risk transient ischemic attack. Low-dose aspirin and a 300-mg loading dose of clopidogrel (Plavix) should be started as soon as imaging rules out hemorrhage. After 10 to 21 days of daily low-dose aspirin and clopidogrel, 75 mg, the patient should be switched to a single antiplatelet drug.

https://www.aafp.org/afp/2019/0915/p378.html

What treatments are recommended for military veterans?

Veterans with chronic musculoskeletal pain and multisystem illness should have symptoms evaluated based on clinical judgment and be treated with a collaborative, team-based approach, including a behavioral health specialist. Veterans with suspected posttraumatic stress disorder should undergo diagnostic evaluation that includes determination of Diagnostic and Statistical Manual of Mental Disorders, 5th ed., criteria and acute risk of harm to self or others. Risk-based management, clinical interventions, comprehensive and regularly updated safety planning, and reliable continuity of care may reduce the risk of suicide.

https://www.aafp.org/afp/2019/1101/p544.html

What treatments has the U.S. Food and Drug Administration approved for pre-exposure HIV prophylaxis?

In addition to once-daily oral treatment with combined tenofovir disoproxil fumarate and emtricitabine (Truvada), the U.S. Food and Drug Administration has approved combined tenofovir alafenamide and emtricitabine

 

 

Copyright © 2020 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


More in Pubmed

MOST RECENT ISSUE


Oct 15, 2020

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article